Advice
Recommended for general use within NHS Scotland.
RECOMMENDATION
In trials of 12 weeks duration, biphasic insulin aspart has demonstrated similar effects on HbA1c levels to biphasic human insulin 30 and biphasic insulin lispro Mix 25. Biphasic insulin aspart 30 has demonstrated similar effects to its competitor insulins and therefore is an effective treatment for diabetes at broadly similar costs.
Download detailed advice22KB (PDF)
Medicine details
- Medicine name:
- Biphasic insulin aspart 30 (NovoMix 30®)
- SMC ID:
- 06/02
- Indication:
- Diabetes mellitus
- Pharmaceutical company
- Novo Nordisk Ltd
- BNF chapter
- Endocrine system
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 06 June 2003